Abbott Laboratories (ABT): Price and Financial Metrics

Abbott Laboratories (ABT): $125.30

0.65 (+0.52%)

POWR Rating

Component Grades














  • ABT scores best on the Sentiment dimension, with a Sentiment rank ahead of 95.38% of US stocks.
  • ABT's strongest trending metric is Value; it's been moving up over the last 48 weeks.
  • ABT ranks lowest in Momentum; there it ranks in the 40th percentile.

ABT Stock Summary

  • Abbott Laboratories's market capitalization of $220,981,682,553 is ahead of 99.1% of US-listed equities.
  • Abbott Laboratories's stock had its IPO on January 1, 1986, making it an older stock than 92.67% of US equities in our set.
  • In terms of volatility of its share price, ABT is more volatile than only 4.53% of stocks we're observing.
  • Stocks that are quantitatively similar to ABT, based on their financial statements, market capitalization, and price volatility, are DHR, TMO, NVO, MDT, and VZ.
  • ABT's SEC filings can be seen here. And to visit Abbott Laboratories's official web site, go to

ABT Valuation Summary

  • ABT's price/earnings ratio is 35.1; this is 3.84% lower than that of the median Healthcare stock.
  • Over the past 243 months, ABT's price/sales ratio has gone up 0.3.
  • Over the past 243 months, ABT's price/earnings ratio has gone down 10.1.

Below are key valuation metrics over time for ABT.

Stock Date P/S P/B P/E EV/EBIT
ABT 2021-08-31 5.6 6.6 35.1 30.2
ABT 2021-08-30 5.5 6.6 35.0 30.1
ABT 2021-08-27 5.5 6.5 34.6 29.8
ABT 2021-08-26 5.5 6.5 34.9 30.0
ABT 2021-08-25 5.5 6.5 34.7 29.8
ABT 2021-08-24 5.5 6.5 34.9 30.0

ABT Growth Metrics

  • Its 5 year price growth rate is now at 104.25%.
  • Its 4 year revenue growth rate is now at 57.38%.
  • Its year over year net income to common stockholders growth rate is now at 59.93%.
ABT's revenue has moved up $9,831,000,000 over the prior 33 months.

The table below shows ABT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 40,233 10,629 6,376
2021-03-31 37,338 9,823 5,724
2020-12-31 34,608 7,901 4,495
2020-09-30 32,221 6,519 3,382
2020-06-30 31,444 6,401 3,110
2020-03-31 32,095 6,139 3,579

ABT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ABT has a Quality Grade of B, ranking ahead of 76.55% of graded US stocks.
  • ABT's asset turnover comes in at 0.559 -- ranking 68th of 677 Pharmaceutical Products stocks.
  • DVAX, RARE, and CORT are the stocks whose asset turnover ratios are most correlated with ABT.

The table below shows ABT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.559 0.557 0.230
2021-03-31 0.527 0.568 0.205
2020-12-31 0.499 0.566 0.166
2020-09-30 0.473 0.567 0.135
2020-06-30 0.462 0.576 0.128
2020-03-31 0.473 0.584 0.147

ABT Price Target

For more insight on analysts targets of ABT, see our ABT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $132.05 Average Broker Recommendation 1.46 (Moderate Buy)

ABT Stock Price Chart Interactive Chart >

Price chart for ABT

ABT Price/Volume Stats

Current price $125.30 52-week high $129.70
Prev. close $124.65 52-week low $100.34
Day low $124.81 Volume 4,161,500
Day high $125.90 Avg. volume 5,384,770
50-day MA $123.86 Dividend yield 1.44%
200-day MA $118.32 Market Cap 222.13B

Abbott Laboratories (ABT) Company Bio

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013. (Source:Wikipedia)

ABT Latest News Stream

Event/Time News Detail
Loading, please wait...

ABT Latest Social Stream

Loading social stream, please wait...

View Full ABT Social Stream

Latest ABT News From Around the Web

Below are the latest news stories about Abbott Laboratories that investors may wish to consider to help them evaluate ABT as an investment opportunity.

Abbott (ABT) Stock Sinks As Market Gains: What You Should Know

Abbott (ABT) closed at $124.65 in the latest trading session, marking a -0.38% move from the prior day.

Yahoo | September 22, 2021

U.S. government to buy point-of-care COVID-19 tests from Abbott, Celltrion -source

The U.S. government has agreed to purchase point-of care COVID-19 tests from Abbott Laboratories and Celltrion Inc to ship to nursing homes and other high risk populations as part of its broader plan to purchase $2 billion in rapid coronavirus tests, a person familiar with the matter said on Tuesday. The federal government will purchase tests as needed and has agreed to spend up to $626 million in its agreement with Celltrion and $554.4 million in its deal with Abbott, the person said.

Yahoo | September 21, 2021

Abbott's (ABT) Portico With FlexNav System Gets FDA Approval

Abbott's (ABT) Portico with FlexNav TAVR system is intended to treat people with symptomatic severe aortic stenosis who are at high or extreme risk for open-heart surgery.

Yahoo | September 21, 2021

Elon Musk chips in $50 million for SpaceX Inspiration4’s children’s cancer fundraising effort

Billionaire Jared Isaacman, who paid for the SpaceX Inspiration4 flight, pledged $100 million St. Jude Children's Research Hospital and set a goal of raising an additional $100 million by February 2022.

Yahoo | September 20, 2021

Abbott Receives FDA Approval for Minimally Invasive Portico™ with FlexNav™ TAVR System to Treat Patients with Aortic Valve Disease

Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's Portico™ with FlexNav™ transcatheter aortic valve replacement (TAVR) system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery. With this latest TAVR (also referred to as TAVI, or transcatheter aortic valve implantation) advancement, Abbott continues to offer the industry's leading portfolio of structural heart solutions that

Yahoo | September 20, 2021

Read More 'ABT' Stories Here

ABT Price Returns

1-mo 0.45%
3-mo 11.58%
6-mo 3.42%
1-year 26.01%
3-year 82.02%
5-year 225.29%
YTD 15.76%
2020 28.04%
2019 22.08%
2018 29.06%
2017 52.03%
2016 -12.32%

ABT Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full ABT Dividend History

Continue Researching ABT

Here are a few links from around the web to help you further your research on Abbott Laboratories's stock as an investment opportunity:

Abbott Laboratories (ABT) Stock Price | Nasdaq
Abbott Laboratories (ABT) Stock Quote, History and News - Yahoo Finance
Abbott Laboratories (ABT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9065 seconds.